Galectin Therapeutics Inc (NASDAQ:GALT) CFO Jack W. Callicutt sold 3,349 shares of the firm’s stock in a transaction on Wednesday, April 4th. The stock was sold at an average price of $5.00, for a total transaction of $16,745.00. Following the completion of the sale, the chief financial officer now owns 4,609 shares in the company, valued at approximately $23,045. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Shares of Galectin Therapeutics stock traded up $0.11 during midday trading on Friday, hitting $4.68. The company had a trading volume of 260,084 shares, compared to its average volume of 661,166. Galectin Therapeutics Inc has a 1-year low of $1.28 and a 1-year high of $6.74. The company has a market cap of $178.08, a price-to-earnings ratio of -9.55 and a beta of 2.53.
Galectin Therapeutics (NASDAQ:GALT) last posted its quarterly earnings results on Thursday, March 29th. The company reported ($0.07) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.11) by $0.04. analysts anticipate that Galectin Therapeutics Inc will post -0.48 earnings per share for the current year.
Several brokerages have recently issued reports on GALT. ValuEngine downgraded shares of Galectin Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday. Zacks Investment Research upgraded shares of Galectin Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, February 6th. Roth Capital lowered their price objective on shares of Galectin Therapeutics from $10.00 to $3.00 and set a “buy” rating on the stock in a research note on Thursday, December 7th. Finally, HC Wainwright restated a “buy” rating and issued a $10.00 price objective (up previously from $6.00) on shares of Galectin Therapeutics in a research note on Thursday, December 7th. One analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $6.44.
WARNING: “Galectin Therapeutics Inc (GALT) CFO Sells $16,745.00 in Stock” was reported by Ticker Report and is the property of of Ticker Report. If you are accessing this piece on another website, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be read at https://www.tickerreport.com/banking-finance/3336276/galectin-therapeutics-inc-galt-cfo-sells-16745-00-in-stock.html.
Galectin Therapeutics Company Profile
Galectin Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic disease and cancer. The company's lead product candidate includes galectin-3 inhibitor (GR-MD-02), a galactoarabino-rhamnogalacturonan polysaccharide polymer for the treatment of liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis patients, as well as for the treatment of cancer.
Receive News & Ratings for Galectin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.